Skip to content

IN2PHARMA

Active
Terloonststraat 22 ·1910 Kampenhout, Belgium
KBO/BCE: BE 0895.730.662
Watch Print / PDF
Age18 yrs
Board2
Connections6
Real estate2 parcels · 5,215 m²

Summary

Conclusion

the dossier summarised in one paragraph

The computed 12-month bankruptcy probability of IN2PHARMA is 0.2% (very low). The company has been active since 2008 and the Belgian State Gazette contains no insolvency or warning signals. No processed annual-account figures are available; this conclusion rests on registry and State Gazette data only.

Based on State Gazette and CBE data.

Trust signals

2 signals
Established
Founded in 2008, 18 years in business.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.

Administrative Flags

No administrative flags

Bankruptcy probability (12 mo)

Checked model v1 · free for everyone
0.2% Very low
0%0,5%1,5%4%10%≥25%
Lower-failure-rate sector −Multiple establishment units +Long track record −

Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?

Financials

Annual accounts & ratios

Source: NBB
Financials being processed
NBB has 10 filing(s) on record for this company, latest fiscal year 2024 (verkort). The annual accounts are being processed.
Filings on record
Fiscal year Type Filed Reference
31-12-2024 verkort 10-07-2025 2025-00277052
31-12-2023 verkort 15-05-2024 2024-00090886
31-12-2022 verkort 18-07-2023 2023-00269175
31-12-2021 verkort 15-03-2022 2022-07800417
31-12-2020 verkort 06-04-2021 2021-09800402
31-12-2019 verkort 27-04-2020 2020-10000401
31-12-2018 verkort 31-07-2019 2019-43400123
31-12-2017 verkort 31-08-2018 2018-60800272
31-12-2016 verkort 31-08-2017 2017-56700148
31-12-2015 verkort 28-07-2016 2016-37400408

Directors

Directors & mandates

5 directors
Current directors & mandates
  • ArphiusLegal entity
    Director· perm. rep.: Nico Swinnen
    State Gazette act 24407052 (19-06-2024)
    Current
    01-02-2021 → present
    2 events
    • 19-06-2024 Mandate renewed· Director
    • 01-02-2021 Mandate renewed· Director
  • Ter LoonstLegal entity
    Director· perm. rep.: Caroline Steensels
    State Gazette act 24407052 (19-06-2024)
    Current
    30-06-2017 → present
    7 events
    • 19-06-2024 Mandate renewed· Director
    • 19-06-2024 Appointed· Managing director
    • 01-02-2021 Mandate renewed· Director
    • 01-02-2021 Mandate renewed· Managing director
    • 30-06-2017 Resigned· Director
    • 30-06-2017 Appointed· Director
    • 30-06-2017 Appointed· Managing director
Former directors (3)
  • Arphius
    Director
    State Gazette act 24407052 (19-06-2024)
    Former
    - → 19-06-2024
  • Ter Loonst
    Director
    State Gazette act 24407052 (19-06-2024)
    Former
    - → 19-06-2024
  • Orca ConsultingLegal entity
    Director· perm. rep.: Leo Vervoort
    State Gazette act 15008838 (19-01-2015)
    Former
    - → 29-10-2014
Full appointment history from the Belgian State Gazette. Permanent representatives are shown for corporate directors.

Insolvency mandates

No insolvency mandates (liquidators, administrators) on record for this company.

Legal Structure

NACE primary Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies(70200)
Legal form Public limited company(014)
Incorporation29-01-2008
StatusActive
Postal code1910

Structure & network

Connections & network

6 connected companies
Arphius, Parent company AArphiusTer Loonst, Parent company TLTer LoonstBerkley Benelux, Shared corporate director BBBerkleyBeneluxKHC Leuven, Shared corporate director KLKHC LeuvenXeniT Solutions, Shared corporate director XSXeniTSolutionsBerkley Real Estate, Shared address BRBerkley RealEstateIN2PHARMA IN2PHARMA0895.730.662
Group structureShared directorsShared address / shareholder
Group structure
Arphius
Parent · 4 subsidiaries · 1 location
Control→
Ter Loonst
Parent · 2 subsidiaries · 1 location
Control→
Network connections
Berkley Benelux
Shared corporate director
→
KHC Leuven
Shared corporate director
→
XeniT Solutions
Shared corporate director
→
Berkley Real Estate
Shared address
→
Connections derived from shared directors, addresses, shareholders and group structure in the Belgian State Gazette.

Locations & real estate

Establishment units

2 locations
IN2PHARMA
Terloonststraat 22, 1910 KampenhoutOverige dienstverlenende activiteiten op het gebied van informatie, n.e. g.
since 20142.231.419.078
IN2PHARMA
Kerkstraat 108, 9050 GentOverige dienstverlenende activiteiten op het gebied van informatie
since 20262.388.528.493
Physical sites registered in the Crossroads Bank for Enterprises (CBE).
Parcels2
Ground area5,215 m²
Buildings2
Building footprint2,374 m²
Volume (LiDAR)17,386 m³
Tallest building10.0 m · ±3 fl.

Real-estate footprint

Source: CBE × cadastre · address linking

Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.

Flanders 2 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
44362B0014/00G002 Flanders 3,095 m² 1 · 2,335 m² 9.2 m · 2 fl.
23038B0344/00G000
ProtectedCultural-historical landscape · MonumentKasteel Ter Loonst en omgevingSource ↗
 Flanders 2,120 m² 1 · 39 m² 10.0 m · 3 fl.
Methodology
via registered seat: 1 · via establishment units: 1
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
1 of these parcels carry protected heritage (source: regional heritage registers, Onroerend Erfgoed / patrimoine.brussels).

Publications

Lifecycle & Insolvency Signals

No insolvency signals in the Belgian State Gazette

Belgisch Staatsblad · acts

9 acts
Capital history · 2
11-05-2026
Capital increase: amount: 12400.0, source: Studio Pharma, account: Andere bij de inbreng buiten kapitaal, currency: EUR
11-05-2026
Capital increase: amount: 0.0, source: KDT Consulting, account: Andere bij de inbreng buiten kapitaal, currency: EUR
All acts · 9 updated 3 months ago
2026
11-05-2026 General meeting · Notarial deed · Merger · Dissolution Open-capture extraction·Carl MAERE
  • Filing: 2026-05-04 · IN2PHARMA
  • General meeting: 2026-04-02 · IN2PHARMA
  • Notarial deed: 2026-04-02 · IN2PHARMA
  • Merger: date: 2026-04-02, type: absorption · IN2PHARMA
  • Merger: date: 2026-04-02, type: absorption · IN2PHARMA
  • Dissolution: date: 2026-04-02 · Studio Pharma
  • Dissolution: date: 2026-04-02 · KDT Consulting
  • Accounting effect: 2026-01-01 · IN2PHARMA
  • Approval: description: fusion proposal · IN2PHARMA
  • Power of attorney: scope: formaliteiten bij een ondernemingsloket ... inschrijving/aanpassing van de gegevens ... Kruispuntbank van Ondernemingen ... Administratie van de Belasting over de Toegevoegde Waarde · IN2PHARMA
  • Power of attorney: scope: uitvoering van de voorgaande beslissingen, recipient: bestuurders · IN2PHARMA
  • Capital increase: amount: 12400.0, source: Studio Pharma, account: Andere bij de inbreng buiten kapitaal, currency: EUR · IN2PHARMA
  • Capital increase: amount: 0.0, source: KDT Consulting, account: Andere bij de inbreng buiten kapitaal, currency: EUR · IN2PHARMA
  • Real estate declaration: nee · Studio Pharma
  • Real estate declaration: nee · KDT Consulting
  • Filing: 2026-02-05 · IN2PHARMA
  • Filing: 2026-02-10 · Studio Pharma
  • Filing: 2026-02-18 · KDT Consulting
  • Registration event: 2026-02-12 · IN2PHARMA
  • Registration event: 2026-02-18 · Studio Pharma
  • Registration event: 2026-02-27 · KDT Consulting
  • Publication: 2026-05-11 · IN2PHARMA
  • Act object: MET FUSIE DOOR OVERNEMING GELIJKGESTELDE VERRICHTING
Summary: General meeting · Notarial deed · Merger · DissolutionNotary: Carl MAERE
11-05-2026 General meeting · Notarial deed · Merger · Dissolution Open-capture extraction·Carl MAERE
  • Filing: 2026-04-30 · KDT Consulting
  • General meeting: 2026-04-02 · KDT Consulting
  • Notarial deed: 2026-04-02 · KDT Consulting
  • Merger: date: 2026-04-02, type: met fusie door overneming gelijkgestelde verrichting · KDT Consulting
  • Dissolution: date: 2026-04-02, type: ontbonden zonder vereffening · KDT Consulting
  • Accounting effect: 2026-01-01 · KDT Consulting
  • Officer resignation: date: 2026-04-02, reason: ontslag van rechtswege · PHC Group
  • Power of attorney: date: 2026-04-02, scope: formaliteiten bij een ondernemingsloket · KDT Consulting
  • Registration event: 2026-02-05 · IN2PHARMA
  • Registration event: 2026-02-10 · Studio Pharma
  • Registration event: 2026-02-18 · KDT Consulting
  • Publication: 2026-05-11
  • Act object: MET FUSIE DOOR OVERNEMING GELIJKGESTELDE VERRICHTING
Summary: General meeting · Notarial deed · Merger · DissolutionNotary: Carl MAERE
11-05-2026 General meeting · Merger · Dissolution · Accounting effect Open-capture extraction·Carl MAERE
  • Filing: 2026-04-30 · Studio Pharma
  • Filing: 2026-02-10 · Studio Pharma
  • General meeting: 2026-04-02 · Studio Pharma
  • Merger: date: 2026-04-02, type: absorption, description: met fusie door overneming gelijkgestelde verrichting · Studio Pharma
  • Dissolution: date: 2026-04-02, type: zonder vereffening · Studio Pharma
  • Accounting effect: 2026-01-01 · Studio Pharma
  • Officer resignation: date: 2026-04-02, reason: ontslag van rechtswege ... naar aanleiding van de met fusie door overneming gelijkgestelde verrichting · PHC Group
  • Power of attorney: date: 2026-04-02, scope: formaliteiten bij een ondernemingsloket ... inschrijving/aanpassing van de gegevens ... Kruispuntbank van Ondernemingen ... Administratie van de Belasting over de Toegevoegde Waarde · Studio Pharma
  • Power of attorney: date: 2026-04-02, scope: voorgaande beslissingen uit te voeren · Studio Pharma
  • Publication: 2026-05-11 · Studio Pharma
  • Registration event: 2026-02-18 · Studio Pharma
  • Registration event: 2026-02-12 · IN2PHARMA
  • Registration event: 2026-02-27 · KDT Consulting
  • Filing: 2026-02-05 · IN2PHARMA
  • Filing: 2026-02-18 · KDT Consulting
  • Notarial deed: 2026-04-02 · Studio Pharma
  • Registration event: 2026-04-08 · Studio Pharma
  • Permanent representative · PHC Group
  • Act object: MET FUSIE DOOR OVERNEMING GELIJKGESTELDE VERRICHTING (door
Summary: General meeting · Merger · Dissolution · Accounting effectNotary: Carl MAERE
12-02-2026 Publication in the Belgian Official Gazette, Miscellaneous Miscellaneous
Summary: Fusion proposal
2024
19-06-2024 1 director appointed, 2 resigning, 2 reappointed Director changes
  • Caroline Steensels, Gedelegeerd bestuurder
  • Ter Loonst, Bestuurder
  • Arphius, Bestuurder
  • Caroline Steensels, Bestuurder
  • Nico Swinnen, Bestuurder
Summary: v3.2
2021
28-04-2021 3 reappointed Director changes
  • Swinnen Nico, Bestuurder
  • Steensels Caroline, Bestuurder
  • Steensels Caroline, Gedelegeerd bestuurder
Summary: v3.2
2017
23-10-2017 2 directors appointed, 2 resigning Director changes
  • Caroline Steensels, Bestuurder
  • Caroline Steensels, Gedelegeerd bestuurder
  • Caroline Steensels, Bestuurder
  • Nico Swinnen, Bestuurder
Summary: v3.2
2015
20-04-2015 Articles of association amended Statutes amendment
Summary: v3.2
19-01-2015 Leo Vervoort resigns as director Director changes
  • Leo Vervoort, Bestuurder
Summary: v3.2

Analysis

Ask AI about this company

Checked AI

Soon: ask questions about this dossier, risks, curator, sector comparison, answered from the official data on this page.

TryWhat are the main risks?Any recent red flags?Compare to sector peers
Coming soon

AI due-diligence brief

Checked AI

Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.

Coming soon
The brief is drafted by our AI model at Anthropic in the US, from this dossier's public data. Nothing that identifies you is sent along and we do not keep the brief. Indicative, not legal or investment advice. How it works

Credit advice

verdict per customer and amount

Should this customer buy amount X on invoice? Enter the amount and payment terms, you get an instant GREEN/AMBER/RED verdict, with a suggested ceiling and concrete conditions.

Based on official sources (NBB, CBE, State Gazette). Indicative, not credit advice.

Similar

Similar companies

Same sector, nearest first

Company registry

Company registry (CBE)

Crossroads Bank
Activities
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies70200Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering70220Overige gespecialiseerde wetenschappelijke en technische activiteiten74909Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg74999
Primary activity highlighted.
Names & trade names
Legal nameNL IN2PHARMA
Registered office
Terloonststraat 22
1910 Kampenhout, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.